MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.405
-0.255
-9.59%
After Hours: 2.400 -0.005 -0.21% 19:58 01/26 EST
OPEN
2.430
PREV CLOSE
2.660
HIGH
2.560
LOW
2.230
VOLUME
13.99M
TURNOVER
--
52 WEEK HIGH
3.200
52 WEEK LOW
0.4195
MARKET CAP
128.48M
P/E (TTM)
-3.3998
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Dow Rises 40 Points; Repro Med Systems Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.13% to 31,000.45 while the NASDAQ rose 0.14% to 13,654.77. The S&P also rose, gaining 0.06% to 3,857.61.
Benzinga · 11h ago
Mid-Day Market Update: Crude Oil Down 0.5%; Vir Biotechnology Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.05% to 30,974.77 while the NASDAQ fell 0.03% to 13,632.13. The S&P also rose, gaining 0.08% to 3,852.18.
Benzinga · 13h ago
Vir Biotechnology, AIkido Pharma leads healthcare gainers; Lipocine, Capricor Therapeutics among major losers
Gainers: Vir Biotechnology VIR +39%, AIkido Pharma (AIKI) +37%, Edesa Biotech EDSA +34%, Motus GI Holdings (MOTS) +29%, Regional Health Properties (RHE) +24%.Losers: Lipocine (LPCN) -18%, Capricor Therapeutics (CAPR) -17%, Iterum Therapeutics (ITRM) -14%, ...
Seekingalpha · 14h ago
DJ Seelos Therapeutics Shares Drop 15% After Public Offering Prices
Dow Jones · 15h ago
Seelos Therapeutics to raise ~$31M capital in stock offering
Seelos Therapeutics (SEEL) prices public offering of ~15.24M shares at $2.05/share, with underwriters' overallotment option to purchase up to an additional 2.29M shares.Gross proceeds will be $31.25M.The company intends to use
Seekingalpha · 17h ago
*DJ Seelos Therapeutics Sees Net Proceeds $29.1 Million From Offering
Dow Jones · 17h ago
*DJ Seelos Therapeutics Inc.'s 15.2 Million-Share Offering Prices at $2.05 a Share
Dow Jones · 17h ago
Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 15,243,90...
PR Newswire · 17h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SEEL. Analyze the recent business situations of Seelos Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SEEL stock price target is 8.00 with a high estimate of 12.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 5.22M
% Owned: 9.78%
Shares Outstanding: 53.42M
TypeInstitutionsShares
Increased
7
1.08M
New
19
64.42K
Decreased
7
580.53K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.08%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Raj Mehra
Chief Scientific Officer
Warren Wasiewski
Director
Judith Dunn
Director
Brian Lian
Director
Daniel O'Connor
Director
Richard Pascoe
Independent Director
Wendell Wierenga
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About SEEL
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.